How good is the coverage and how accurate are exposure data in the Swedish Biologics Register (ARTIS)?

Scandinavian Journal of Rheumatology

Volumn 44, Issue 1, 2015, Pages 22-28

  Wadstrom H ^a   Eriksson, J K ^a   Neovius, M ^a   Askling, J ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ETANERCEPT; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL FACTOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ACCURACY; ADULT; AGE; ARTICLE; DEATH; DRUG EXPOSURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL INFORMATION; OUTPATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; REGISTER; RESIDENCY EDUCATION; RHEUMATOID ARTHRITIS; SPONDYLOARTHROPATHY; SWEDISH BIOLOGICS REGISTER; TREATMENT INDICATION; TREATMENT WITHDRAWAL; VALIDITY; ANTAGONISTS AND INHIBITORS; ARTHRITIS, PSORIATIC; MIDDLE AGED; PATIENT IDENTIFICATION; PUBLIC HEALTH; SPONDYLARTHROPATHIES; SPONDYLITIS, ANKYLOSING; STANDARDS; STATISTICS AND NUMERICAL DATA; SWEDEN; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; BIOLOGICAL FACTORS; DRUG PRESCRIPTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NATIONAL HEALTH PROGRAMS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PATIENT IDENTIFICATION SYSTEMS; REGISTRIES; SPONDYLARTHROPATHIES; SPONDYLITIS, ANKYLOSING; SWEDEN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84920854770     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2014.927918     Document Type: Article

References (16)

1. Braun J, Sieper J. Therapy of ankylosing spondylitis and other spondyloarthritides: established medical treatment, anti-TNF-alpha therapy and other novel approaches. Arthritis Res 2002;4:307-21.
2. Upchurch KS, Kay J. Evolution of treatment for rheumatoid arthritis. Rheumatology (Oxford) 2012;51(Suppl 6):vi28-36.
3. Baraliakos X, Braun J. Biologic therapies for spondyloarthritis: what is new? Curr Rheumatol Rep 2012;14:422-7.
4. Cruz Fernandez-Espartero M, Perez-Zafrilla B, Naranjo A, Esteban C, Ortiz AM, Gomez-Reino JJ, et al. Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. Semin Arthritis Rheum 2011;41:524-33.
5. Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 2011;70:1914-20.
6. Watson K, Symmons D, Griffiths I, Silman A. The British Society for Rheumatology biologics register. Ann Rheum Dis 2005;64(Suppl 4):iv42-3.
7. Hetland ML. DANBIO - powerful research database and electronic patient record. Rheumatology (Oxford) 2011;50:69-77.
8. Askling J, Fored CM, Geborek P, Jacobsson LT, van Vollenhoven R, Feltelius N, et al. Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 2006;65:707-12.
9. Dixon WG, Carmona L, Finckh A, Hetland ML, Kvien TK, Landewe R, et al. EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology. Ann Rheum Dis 2010;69:1596-602.
10. Geborek P, Nitelius E, Noltorp S, Petri H, Jacobsson L, Larsson L, et al. Population based studies of biological antirheumatic drug use in southern Sweden: comparison with pharmaceutical sales. Ann Rheum Dis 2005;64:1805-7.
11. Neovius M, Simard J, Sundstrom A, Jacobsson L, Geborek P, Saxne T, et al. Generalisability of clinical registers used for drug safety and comparative effectiveness research: coverage of the Swedish Biologics Register. Ann Rheum Dis 2011;70:516-19.
12. Neovius M, Arkema EV, Olsson H, Eriksson JK, Kristensen LE, Simard JF, et al. Drug survival on TNF inhibitors in patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab. Ann Rheum Dis. Published online: 27 November 2013. doi: 10.1136/annrheumdis-2013-204128.
13. The Dental and Pharmaceutical Benefits Agency(TLV). Available from: www.tlv.se/.
14. Wettermark B, Hammar N, Fored CM, Leimanis A, Otterblad Olausson P, Bergman U, et al. The new Swedish Prescribed Drug Register -opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf 2007;16:726-35.
15. Neovius M, Sundstrom A, Simard J, Wettermark B, Cars T, Feltelius N, et al. Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009. Scand J Rheumatol 2011;40:8-15.
16. Knight A, Sandin S, Askling J. Increased risk of autoimmune disease in families with Wegener's granulomatosis. J Rheumatol 2010;37:2553-8.